3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Active not recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Endocrine
1
CNS
1
Conditions
Neuroendocrine Tumors
14
Carcinoid Tumor
5
Gastro-enteropancreatic neuroendocrine tumor
4
Acromegaly
3
Serotonin Syndrome
2
Pituitary Neoplasms
2
Pheochromocytoma
1
Paraganglioma
1
Neuroendocrine Tumour With Carcinoid Symptoms
1
Neuroendocrine Tumors in Lung
1
Neoplastic Cells, Circulating
1
Neoplasm Metastasis
1
Growth Hormone-Secreting Pituitary Adenoma
1
Gigantism
1
Gastrointestinal Neoplasms
1
Flushing
1
Diarrhea
1
Carcinoma, Hepatocellular
1
Carcinoid Heart Disease
1
Adenoma, Islet Cell
1
Interventions
3-Iodobenzylguanidine
8
lutetium Lu 177 dotatate
6
gallium Ga 68 dotatate
5
Temozolomide
4
Specimen Handling
4
Magnetic Resonance Spectroscopy
4
anlotinib
3
Everolimus
3
olaparib
2
cabozantinib
2
belzutifan
2
Sunitinib
2
Phenoxybenzamine
2
Nivolumab
2
Fluorodeoxyglucose F18
2
Biopsy
2
Axitinib
2
3-fluorobenzylguanidine
2
177Lu-octreotide, DOTA(0)-Tyr(3)-
2
vandetanib
1
talazoparib
1
spartalizumab
1
pembrolizumab
1
pazopanib
1
lanreotide
1
guadecitabine
1
fluorodopa F 18
1
fludarabine phosphate
1
copper dotatate CU-64
1
cixutumumab
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Paraganglioma
×
lanreotide
×
Endocrine
×
Clear all
NCT03946527
2026-03-02
LAMPARA
Columbia University
Phase 2
Active not recruiting
10 enrolled